Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1739-1743

  Pihie, Azimahtol Hawariah Lope ^a   Stanslas, Johnson ^a   Din, Laily Bin ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Antiproliferative activity; Human breast cancer cell lines; Styrylpyrone derivative

Indexed keywords

ANTIESTROGEN; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN; ESTROGEN RECEPTOR; METHYLENE BLUE; PLANT EXTRACT; PROGESTERONE RECEPTOR; STEROID RECEPTOR; STYRYLPYRONE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; HUMAN; HUMAN CELL; KIDNEY CELL; LIVER CELL; PRIORITY JOURNAL; RADIOASSAY; RECEPTOR BINDING;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BREAST NEOPLASMS; CATTLE; CELL DIVISION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ESTRADIOL; FEMALE; HUMANS; KIDNEY; LIVER; PROGESTERONE; PYRONES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0031857478     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Azimahtol HLP, Munawer M and Laily D: Antifertility effect of goniothalamin: A strylpyrone isolated from Goniothalamus tapis moqo. Asia Pacific J Pharmacology 9: 273-277, 1994.
2. King RJB: A discussion of the roles of oestrogen and progestin in human mammary carsinogenesis. J Steroid Biochem Molec Biol 39: 811-818, 1991.
3. Leake, RE: Methodology of steroid hormone receptor determination in breast cancer. In: Progesterone in the management of hormone responsive carcinoma (Taylor RW ed). Oxford, Medicine Publishing Foundation, 1980, pp 3-17.
4. Hissom JR and Moore MR: Progestin effects on growth in the human breast cancer cell line T47D-possible therapeutic implications. Biochem Biophys Res Commun 145: 706-711, 1987.
5. Furr BJA and Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmac Ther 25: 127-205, 1984.
6. Klijn JGM, De Jong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ: and Alexieva-Figusch J: Antiprogestins, a new form of endocrine therapy of human breast cancer. Cancer Res 49: 2851-2856, 1989.
7. Lin L and Hwang LP: Antiproliferative effects of oxygenated sterols: positive correlation with binding affinities for the antiestrogenbinding sites. Biochim Biophys Acta 1082: 177-184, 1991.
8. Berthois Y, Katzenellenbogen JA and Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natn Acad Sei U.S.A. 83: 2496-2500, 1986.
9. Milgrom E, Thi L, Alger M and Baulieu EE: Mechanisms regulating the concentration and conformation of progesterone receptor(s) in the uterus. J Biol Chem 248: 6366-6374, 1973.
10. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
11. Wakeling AE and Slater SR: Estrogen receptor binding and biological activity of tamoxifen and its metabolites. Cancer Treat Rep 64: 741-744, 1980.
12. Page MJ, Field JK, Everett NP and Green CD: Serum regulation of the estrogen responsiveness - of the human breast cancer cell line MCF-7. Cancer Res 43: 1244-1250, 1983.
13. Katzenellenbogen BS, Miller MA, Mullick A and Sheen YY: Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res Treat 5: 231-243, 1985.
14. Horwitz KB, Mockus MB and Lessy BA: Variant T47D human breast cancer with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell 28: 633-642, 1982.